Literature DB >> 27748373

Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation.

J Kanda1,2, Y Morishima3, S Terakura4, A Wake5, N Uchida5, S Takahashi6, Y Ono7, Y Onishi8, H Kanamori9, N Aotsuka10, Y Ozawa11, H Ogawa12, T Sakura13, K Ohashi14, T Ichinohe15, K Kato16, Y Atsuta17,18, T Teshima19, M Murata4.   

Abstract

The effect of graft-versus-host disease (GVHD) on transplant outcomes after unrelated cord blood transplantation (UCBT) has not been fully elucidated. We analyzed the impact of acute and chronic GVHD on outcomes in adult patients with acute leukemia or myelodysplastic syndrome who underwent their first UCBT (n=2558). The effect of GVHD on outcomes was analyzed after adjusting for other significant variables. The occurrence of GVHD was treated as a time-dependent covariate. The occurrence of grade 1-2 or 3-4 acute GVHD was significantly associated with a lower relapse rate. Grade 3-4 acute GVHD was associated with a higher risk of non-relapse and overall mortality than no acute GVHD, whereas grade 1-2 acute GVHD was associated with a lower risk of non-relapse and overall mortality than no acute GVHD. Limited or extensive chronic GVHD was significantly associated with a lower relapse rate. Limited chronic GVHD was associated with a lower overall and non-relapse mortality than no chronic GVHD. In conclusion, mild acute or chronic GVHD was associated not only with a low risk of relapse but also with a low risk of non-relapse mortality, and provides a survival benefit in UCBT.

Entities:  

Mesh:

Year:  2016        PMID: 27748373     DOI: 10.1038/leu.2016.288

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.

Authors:  Junya Kanda; Katsutsugu Umeda; Koji Kato; Makoto Murata; Junichi Sugita; Souichi Adachi; Katsuyoshi Koh; Maiko Noguchi; Hiroaki Goto; Nao Yoshida; Maho Sato; Yuhki Koga; Tsukasa Hori; Yuko Cho; Atsushi Ogawa; Masami Inoue; Yoshiko Hashii; Yoshiko Atsuta; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2020-03-11       Impact factor: 5.483

Review 2.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

3.  Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.

Authors:  Jaime Sanz; Mi Kwon; Guiomar Bautista; Miguel A Sanz; Pascual Balsalobre; José Luis Piñana; Carlos Solano; Rafael Duarte; Christelle Ferrá; Ignacio Lorenzo; Carmen Martín; Pere Barba; María Jesús Pascual; Rodrigo Martino; Jorge Gayoso; Ismael Buño; Carmen Regidor; Almudena de la Iglesia; Juan Montoro; José Luis Díez-Martín; Guillermo F Sanz; Rafael Cabrera
Journal:  Blood Adv       Date:  2017-06-20

4.  High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.

Authors:  Juliet N Barker; Sean M Devlin; Kristine A Naputo; Kelcey Skinner; Molly A Maloy; Lisa Flynn; Theodora Anagnostou; Scott T Avecilla; Andromachi Scaradavou; Christina Cho; Parastoo B Dahi; Sergio A Giralt; Boglarka Gyurkocza; Alan M Hanash; Katharine Hsu; Ann A Jakubowski; Esperanza B Papadopoulos; Jonathan U Peled; Miguel-Angel Perales; Craig S Sauter; Gunjan L Shah; Brian C Shaffer; Roni Tamari; James W Young; Mikhail Roshal; Richard J O'Reilly; Doris M Ponce; Ioannis Politikos
Journal:  Blood Adv       Date:  2020-12-08

5.  HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation.

Authors:  T Yabe; F Azuma; K Kashiwase; K Matsumoto; T Orihara; H Yabe; S Kato; K Kato; S Kai; T Mori; S Morishima; M Satake; M Takanashi; K Nakajima; Y Morishima
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

6.  GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.

Authors:  S Terakura; Y Kuwatsuka; S Yamasaki; A Wake; J Kanda; Y Inamoto; S Mizuta; T Yamaguchi; N Uchida; Y Kouzai; N Aotsuka; H Ogawa; H Kanamori; K Nishiwaki; S Miyakoshi; M Onizuka; I Amano; T Fukuda; T Ichinohe; Y Atsuta; M Murata; T Teshima
Journal:  Bone Marrow Transplant       Date:  2017-06-12       Impact factor: 5.483

7.  Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.

Authors:  Nobuhiko Imahashi; Seitaro Terakura; Eisei Kondo; Koji Kato; Sung-Won Kim; Akihito Shinohara; Mizuki Watanabe; Takahiro Fukuda; Naoyuki Uchida; Hikaru Kobayashi; Jun Ishikawa; Keisuke Kataoka; Souichi Shiratori; Takashi Ikeda; Ken-Ichi Matsuoka; Shuro Yoshida; Tadakazu Kondo; Takafumi Kimura; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Junya Kanda
Journal:  Bone Marrow Transplant       Date:  2021-11-24       Impact factor: 5.483

8.  The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Authors:  Junya Kanda; Hiromi Hayashi; Annalisa Ruggeri; Fumihiko Kimura; Fernanda Volt; Satoshi Takahashi; Shinichi Kako; Karina Tozatto-Maio; Masamitsu Yanada; Guillermo Sanz; Naoyuki Uchida; Emanuele Angelucci; Seiko Kato; Mohamad Mohty; Edouard Forcade; Masatsugu Tanaka; Jorge Sierra; Takanori Ohta; Riccardo Saccardi; Takahiro Fukuda; Tatsuo Ichinohe; Takafumi Kimura; Vanderson Rocha; Shinichiro Okamoto; Arnon Nagler; Yoshiko Atsuta; Eliane Gluckman
Journal:  Bone Marrow Transplant       Date:  2021-10-11       Impact factor: 5.483

Review 9.  Hematopoietic stem cell transplantation for acute myeloid leukemia.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

10.  Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

Authors:  Shannon R McCurdy; Christopher G Kanakry; Hua-Ling Tsai; Ivana Gojo; B Douglas Smith; Douglas E Gladstone; Javier Bolaños-Meade; Ivan Borrello; William H Matsui; Lode J Swinnen; Carol Ann Huff; Robert A Brodsky; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-30       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.